Met Life Investment Management, LLC Alpine Immune Sciences, Inc. Transaction History

Met Life Investment Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$17.75 - $41.6 $349,692 - $819,561	19,701 New	19,701 $780,000
Q3 2023 May 09, 2024	BUY	$10.13 - $13.98 $48,522 - $66,964	4,790 Added 39.82%	16,818 $192,000
Q2 2023 Apr 29, 2024	BUY	$6.84 - $11.91 $115,035 - $200,302	16,818 New	16,818 $172,000
Q2 2023 Aug 10, 2023	BUY	$6.84 - $11.91 $32,763 - $57,048	4,790 Added 39.82%	16,818 $172,000
Q1 2023 May 09, 2024	BUY	$7.0 - $8.75 $84,196 - $105,245	12,028 New	12,028 $92.9 Million
Q4 2022 May 10, 2024	BUY	$5.45 - $7.35 $65,552 - $88,405	12,028 New	12,028 $88,000
Q4 2022 Feb 15, 2023	BUY	$5.45 - $7.35 $65,552 - $88,405	12,028 New	12,028 $88,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.